NASDAQ:IMAB I-Mab (IMAB) Stock Price, News & Analysis $1.78 -0.10 (-5.08%) As of 11:14 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About I-Mab Stock (NASDAQ:IMAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get I-Mab alerts:Sign Up Key Stats Today's Range$1.76▼$2.0150-Day Range$0.62▼$1.8752-Week Range$0.60▼$2.00Volume944,291 shsAverage Volume333,955 shsMarket Capitalization$144.95 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company OverviewI-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.Read More… I-Mab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreIMAB MarketRank™: I-Mab scored higher than 52% of companies evaluated by MarketBeat, and ranked 555th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingI-Mab has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageI-Mab has only been the subject of 2 research reports in the past 90 days.Read more about I-Mab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for I-Mab are expected to decrease in the coming year, from ($0.56) to ($1.35) per share.Price to Book Value per Share RatioI-Mab has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.45% of the float of I-Mab has been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in I-Mab has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldI-Mab does not currently pay a dividend.Dividend GrowthI-Mab does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.45% of the float of I-Mab has been sold short.Short Interest Ratio / Days to CoverI-Mab has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in I-Mab has recently increased by 7.84%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.34 News SentimentI-Mab has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for I-Mab this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for IMAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, I-Mab insiders have not sold or bought any company stock.Percentage Held by Insiders22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 38.38% of the stock of I-Mab is held by institutions.Read more about I-Mab's insider trading history. Receive IMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for I-Mab and its competitors with MarketBeat's FREE daily newsletter. Email Address IMAB Stock News HeadlinesI-Mab to Participate in the H.C. Wainwright “HCW@Home” SeriesJune 4 at 12:51 AM | finance.yahoo.comI-Mab Advances Givastomig in Gastric Cancer with Promising Clinical DataJune 2 at 7:41 AM | tipranks.comWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington. June 4, 2025 | Altimetry (Ad)I-Mab stock surges on Lucid Capital’s buy rating initiationMay 30, 2025 | za.investing.comI-Mab stock surges on Lucid Capital's buy rating initiationMay 28, 2025 | investing.comI-Mab to Present at Jefferies Global Healthcare Conference and Share New Givastomig Data at ESMO GI Cancers Congress 2025May 21, 2025 | nasdaq.comI-Mab to Present at Jefferies Global Healthcare ConferenceMay 20, 2025 | globenewswire.comI-Mab’s Financial Report Highlights Givastomig ProgressMay 17, 2025 | tipranks.comSee More Headlines IMAB Stock Analysis - Frequently Asked Questions How have IMAB shares performed this year? I-Mab's stock was trading at $0.85 at the beginning of 2025. Since then, IMAB stock has increased by 120.0% and is now trading at $1.87. View the best growth stocks for 2025 here. When did I-Mab IPO? I-Mab (IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at a price of $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers. Who are I-Mab's major shareholders? I-Mab's top institutional investors include Stonepine Capital Management LLC (0.59%), Ground Swell Capital LLC (0.08%) and HBK Sorce Advisory LLC (0.06%). How do I buy shares of I-Mab? Shares of IMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of I-Mab own? Based on aggregate information from My MarketBeat watchlists, some other companies that I-Mab investors own include NVIDIA (NVDA), Tesla (TSLA), CrowdStrike (CRWD), NIO (NIO), Plug Power (PLUG), HubSpot (HUBS) and Intel (INTC). Company Calendar Today6/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMAB CIK1778016 Webwww.i-mabbiopharma.com Phone86-21-6057-8000FaxN/AEmployees380Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$7.00 Low Stock Price Target$4.00 Potential Upside/Downside+188.0%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio15.99 Quick Ratio15.99 Sales & Book Value Annual Sales$3.27 million Price / Sales47.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.93 per share Price / Book0.65Miscellaneous Outstanding Shares81,660,000Free Float63,489,000Market Cap$155.97 million OptionableOptionable Beta1.13 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:IMAB) was last updated on 6/4/2025 by MarketBeat.com Staff From Our PartnersThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredFPV Drone Innovator Secures Major Defense ContractIn May, Ukraine launched Operation Spider Web - a 117-drone FPV swarm that devastated Russian fuel depots and ...The Tomorrow Investor | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Recession Already Started, Are You Prepared?Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Ame...Lear Capital | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding I-Mab Please log in to your account or sign up in order to add this asset to your watchlist. Share I-Mab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.